| Literature DB >> 26345617 |
Jiufu Qin1,2, Yongjin J Zhou2, Anastasia Krivoruchko2,3, Mingtao Huang2,3, Lifang Liu2,3, Sakda Khoomrung2, Verena Siewers2,3, Bo Jiang1, Jens Nielsen2,3,4.
Abstract
Baker's yeast Saccharomyces cerevisiae is an attractive cell factory for production of chemicals and biofuels. Many different products have been produced in this cell factory by reconstruction of heterologous biosynthetic pathways; however, endogenous metabolism by itself involves many metabolites of industrial interest, and de-regulation of endogenous pathways to ensure efficient carbon channelling to such metabolites is therefore of high interest. Furthermore, many of these may serve as precursors for the biosynthesis of complex natural products, and hence strains overproducing certain pathway intermediates can serve as platform cell factories for production of such products. Here we implement a modular pathway rewiring (MPR) strategy and demonstrate its use for pathway optimization resulting in high-level production of L-ornithine, an intermediate of L-arginine biosynthesis and a precursor metabolite for a range of different natural products. The MPR strategy involves rewiring of the urea cycle, subcellular trafficking engineering and pathway re-localization, and improving precursor supply either through attenuation of the Crabtree effect or through the use of controlled fed-batch fermentations, leading to an L-ornithine titre of 1,041±47 mg l(-1) with a yield of 67 mg (g glucose)(-1) in shake-flask cultures and a titre of 5.1 g l(-1) in fed-batch cultivations. Our study represents the first comprehensive study on overproducing an amino-acid intermediate in yeast, and our results demonstrate the potential to use yeast more extensively for low-cost production of many high-value amino-acid-derived chemicals.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26345617 PMCID: PMC4569842 DOI: 10.1038/ncomms9224
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919
Figure 1Schematic overview of L-ornithine biosynthesis in S. cerevisiae and the main metabolic engineering targets implemented in this study.
Genes or proteins subject to overexpression are shown in red font, while those subject to downregulation or deletion are shown in green and blue, respectively. Solid arrows represent single reaction steps, while the dashed arrows represent multiple reaction steps. The green arrows represent the related genes or proteins subject to downregulation, while the red arrows indicate that the related genes or proteins are subject to overexpression. The blue arrows indicate that the related genes are subject to deletion. CAR1, arginase; CAR2, L-ornithine transaminase; ARG3, ornithine carbamoyltransferase; ARG2, glutamate N-acetyltransferase; ARG5,6, acetylglutamate kinase and N-acetyl-gamma-glutamyl-phosphate reductase; ARG7, mitochondrial ornithine acetyltransferase; ARG8, acetylornithine aminotransferase; MLS-argJ, ornithine acetyltransferase from C. glutamicum located to the mitochondria of S. cerevisiae; MLS-argB, acetylglutamate kinase from C. glutamicum located to the mitochondria of S. cerevisiae; argA, glutamate N-acetyltransferase from E. coli; argB, acetylglutamate kinase from E. coli; argC, N-acetyl-gamma-glutamyl-phosphate reductase from C. glutamicum; argD, acetylornithine aminotransferase from C. glutamicum; argJ, ornithine acetyltransferase from C. glutamicum; ORT1, ornithine transporter of the mitochondrial inner membrane; AGC1, glutamate uniporter; ODC1, transporter of α-ketodicarboxylate or α-ketoglutarate of the mitochondrial inner membrane; GDH1, NADP+-dependent glutamate dehydrogenase; GDH3, NADP+-dependent glutamate dehydrogenase; GLT1, NAD+-dependent glutamate synthase; GLN1, glutamine synthetase; GDH2, NAD+-dependent glutamate dehydrogenase; CIT1, citrate synthase; PYC2, pyruvate carboxylase isoform; ACO2, putative mitochondrial aconitase isozyme; IDP1, mitochondrial NADP+-specific isocitrate dehydrogenase; PDA1, E1 alpha subunit of the pyruvate dehydrogenase (PDH) complex; PDA1[S313A], PDA1 with mutation S313A; KGD2, dihydrolipoyl transsuccinylase; MTH1-ΔT, truncated version of MTH1; Ndi1p, NADH:ubiquinone oxidoreductase. TCA, tricarboxylic acid cycle; EMP, the glycolysis pathway; HXT, hexose transporter; AOX, NADH alternative oxidase; Q, ubiquinone. Respiratory chain (complexes III–IV) in the mitochondrial inner membrane is shown as a rectangle, while the ATP synthase (complex V) is shown as a square. Orn, L-ornithine; Glu, L-glutamate; Gln, L-glutamine; Arg, L-arginine; Cit, L-citrulline; Pro, L-proline; ACTGlu, N-acetyl-L-glutamate; ACTGlu-P, N-acetylglutamyl-P; ACTGlu-SA, N-acetylglutamate semialdehyde; ACTOrn, N-acetylornithine; AKG, α-ketoglutarate; CIT, citrate; ACO, aconitate; ICI, isocitrate; OAA, oxaloacetate; AcCoA, acetyl CoA; PYR, pyruvate; SUCC, succinyl-CoA; EtOH, ethanol; ALD, acetaldehyde; Glc, glucose.
Main strains used for module and full pathway optimization
| 1 | M1a | M1a | Null | Null | Null | Null | |
| 2 | M1b | M1b | Null | Null | Null | Null | |
| 3 | M1c | M1c | Null | Null | Null | Null | |
| 4 | M1cM2a | M1c | M2a | Null | Null | ||
| 5 | M1cM2b | M1c | M2b | Null | Null | ||
| 6 | M1cM2c | M1c | M2c | Null | Null | ||
| 7 | M1cM2d | M1c | M2d | Null | Null | ||
| 8 | M1cM2e | M1c | M2e | Null | Null | ||
| 9 | M1cM2f | M1c | M2f | Null | Null | ||
| 10 | M1cM2g | M1c | M2g | Null | Null | ||
| 11 | M1cM2h | M1c | M2h | Null | Null | ||
| 12 | M1cM2i | M1c | M2i | Null | Null | ||
| 13 | M1cM2j | M1c | M2j | Null | Null | ||
| 14 | M1cM2k | M1c | M2k | Null | Null | ||
| 15 | M1cM2l | M1c | M2l | Null | Null | ||
| 16 | M1cM2m | M1c | M2m | Null | Null | ||
| 17 | M1cM2n | M1c | M2n | Null | Null | ||
| 18 | M1cM2o | M1c | M2o | Null | Null | ||
| 19 | M1cM2p | M1c | M2p | Null | Null | ||
| 20 | M1cM2q | M1c | M2q | Null | Null | ||
| 21 | M1cM2r | M1c | M2r | Null | Null | ||
| 22 | M1cM2s | M1c | M2s | Null | Null | ||
| 23 | M1cM2t | M1c | M2t | Null | Null | ||
| 24 | M1cM2qM3a | M1c | M2q | M3a | |||
| 25 | M1cM2qM3b | M1c | M2q | M3b | |||
| 26 | M1cM2qM3c | M1c | M2q | M3c | |||
| 27 | M1cM2qM3d | M1c | M2q | M3d | |||
| 28 | M1cM2qM3e | M1c | M2q | M3e | |||
| 29 | M1cM2qM3f | M1c | M2q | M3f | |||
| 30 | M1dM2q | M1d | M2q | Null | Null | ||
| 31 | M1dM2qM3c | M1d | M2q | M3c | |||
| 32 | M1dM2qM3e | M1d | M2q | M3e | |||
| 33 | M1dM2qM3f | M1d | M2q | M3f | |||
| 34 | B0166A (ORT1) | Null | Null | Null | Null | Null | Null |
Strain names indicate the modules present in the strain, for example, M1aM2bM3c includes strategy a for Module 1, strategy b for Module 2 and strategy c for Module 3.
Figure 2Leaky L-arginine auxotrophy enables L-ornithine overproduction.
(a) The MPR was initiated from Module 1. CAR1, arginase; CAR2, L-ornithine transaminase; ARG3, ornithine carbamoyltransferase. See Figure 1 legend regarding abbreviations. The attenuation of ARG3 was implemented by replacing the original promoter of ARG3 with the HXT1 or KEX2 promoter (P-ARG3 and P-ARG3, respectively). (b) The transcriptional downregulation of Arg3p and knockout of L-ornithine potential consumption step Car2p led to L-ornithine overproduction. Blue solid circle indicates that the molecular implementation is included in the strain under test. Cells were grown in defined minimal medium with 20 gl−1 glucose and cultures were sampled after 72 h of growth for L-ornithine detection. Displayed are the average values±s.d. from at least three biological replicates. (c) The transcriptional downregulation of Arg3p decreased the intracellular L-arginine pool. Cells were grown in defined minimal medium with 20 gl−1 glucose and cultures were sampled in both glucose phase (OD600 is between 0.8 and 1.2 approximately) and ethanol phase (OD600 is up to 4–5) for L-arginine and biomass detection. All data are presented as the mean±s.d. (n≥3).
Figure 3Subcellular trafficking engineering and pathway translocation elevates L-ornithine synthesis.
To coordinate transport and biosynthesis of L-ornithine, we applied three different strategies: (a) improving mitochondrial L-ornithine biosynthesis combined with engineering of transporters [strategy (i)]; (b) improving biosynthesis of mitochondrial L-ornithine biosynthesis combined with translocation of glutamate biosynthesis to the mitochondria [strategy (ii)]; and (c) translocation of the whole L-ornithine biosynthetic pathway to the cytoplasm [strategy (iii)]. In a–c, fonts and arrows are as described in legend to Fig. 1. ARG2, glutamate N-acetyltransferase; ARG5,6, acetylglutamate kinase and N-acetyl-gamma-glutamyl-phosphate reductase; ARG7, mitochondrial ornithine acetyltransferase; ARG8, acetylornithine aminotransferase; MLS-argJ, ornithine acetyltransferase from C. glutamicum located to the mitochondria of S. cerevisiae; MLS-argB, acetylglutamate kinase from C. glutamicum located to the mitochondria of S. cerevisiae; argA, glutamate N-acetyltransferase from E. coli; argB, acetylglutamate kinase from E. coli; argC, N-acetyl-gamma-glutamyl-phosphate reductase from C. glutamicum; argD, acetylornithine aminotransferase from C. glutamicum; argJ, ornithine acetyltransferase from C. glutamicum; ORT1, ornithine transporter of the mitochondrial inner membrane; AGC1, glutamate uniporter; ODC1, transporter of α-ketodicarboxylate or α-ketoglutarate of the mitochondrial inner membrane; GDH1, NADP+-dependent glutamate dehydrogenase; GDH3, NADP+-dependent glutamate dehydrogenase; GLT1, NAD+-dependent glutamate synthase; GLN1, glutamine synthetase; GDH2, NAD+-dependent glutamate dehydrogenase; MLS-GDH1, mitochondrially targeted NADP+-dependent glutamate dehydrogenase; MLS-GDH2, mitochondrially targeted NAD+-dependent glutamate dehydrogenase. See Fig. 1 legend regarding abbreviations of metabolites. (d) Pathway variants in Module 2 enable substantial increase in L-ornithine titre. Cells were grown in defined minimal medium with 20 gl−1 glucose, and cultures were sampled after 72 h of growth for L-ornithine detection. Displayed is the average values±s.d. (n≥3).
Figure 4Attenuation of the ‘Crabtree effect' improves carbon channelling to L-ornithine (Module 3).
To overcome the ‘Crabtree effect' we evaluated three different strategies: (a) strategy (i) overexpression of TCA cycle genes involved in the biosynthesis of α-ketoglutarate; (b) strategy (ii) improving consumption of NADH generated in connection with α-ketoglutarate biosynthesis; and (c) strategy (iii) attenuating the glucose uptake rate and hereby reducing overflow metabolism to ethanol. See Fig. 1 legend regarding abbreviations of genes and metabolites. (d) Strains with variant pathways in Module 3 led to increased production of L-ornithine. Cells were grown in defined minimal medium with 20 gl−1 glucose and cultures were sampled after 72 h of growth for L-ornithine quantification. Exceptionally, cultures were sampled after 108 h of growth for strain M1cM2qM3e and M1dM2qM3e as ΔT-MTH1 overexpression impaired the glucose uptake accompanied by the decreased growth rate. Displayed is the average values±s.d. from at least three biological replicates. (e) Physiological characterization of the strain expressing MTH1-ΔT and the control. The blue solid circle represents the strain harbouring MTH1-ΔT, while the grey one represents the one without MTH1-ΔT. The specific growth rate: μmax (h−1), specific ethanol production rate: rEOH (g ethanol (g DCW)−1 h−1) and specific glucose uptake rate: rglu (g glucose (g DCW)−1 h−1) are shown. All values were calculated in batch culture on glucose during the exponential growth phase. (f) Physiological characterization of the strain harbouring MTH1-ΔT and the control. The blue solid circle represents the strain harbouring MTH1-ΔT, while the grey one represents the one without MTH1-ΔT. The biomass yield on glucose: Y ((g DCW) (g glucose)−1), the L-ornithine yield on glucose: YORN/S (mg L-ornithine (g glucose)−1) and the ethanol yield on glucose: Y (g ethanol (g glucose)−1) are shown. All values were calculated in batch cultures on glucose during the exponential growth phase. All data are presented as the mean±s.d. (n≥3).